Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Artiva Biotherapeutics (ARTV) Research & Development (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Research & Development for 3 consecutive years, with $17.0 million as the latest value for Q4 2025.

  • For Q4 2025, Research & Development rose 27.61% year-over-year to $17.0 million; the TTM value through Dec 2025 reached $69.5 million, up 38.17%, while the annual FY2025 figure was $69.5 million, 38.17% up from the prior year.
  • Research & Development hit $17.0 million in Q4 2025 for Artiva Biotherapeutics, down from $17.6 million in the prior quarter.
  • Across five years, Research & Development topped out at $17.9 million in Q2 2025 and bottomed at $11.2 million in Q4 2023.
  • Average Research & Development over 3 years is $14.1 million, with a median of $13.3 million recorded in 2024.
  • Year-over-year, Research & Development grew 3.51% in 2024 and then surged 52.85% in 2025.
  • Artiva Biotherapeutics' Research & Development stood at $11.2 million in 2023, then rose by 19.4% to $13.3 million in 2024, then increased by 27.61% to $17.0 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $17.0 million, $17.6 million, and $17.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.